1. Home
  2. FTV vs DGX Comparison

FTV vs DGX Comparison

Compare FTV & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortive Corporation

FTV

Fortive Corporation

HOLD

Current Price

$53.88

Market Cap

16.3B

Sector

Industrials

ML Signal

HOLD

Logo Quest Diagnostics Incorporated

DGX

Quest Diagnostics Incorporated

HOLD

Current Price

$182.89

Market Cap

20.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTV
DGX
Founded
2015
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.3B
20.5B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
FTV
DGX
Price
$53.88
$182.89
Analyst Decision
Hold
Buy
Analyst Count
11
15
Target Price
$56.09
$194.07
AVG Volume (30 Days)
3.0M
1.2M
Earning Date
10-29-2025
10-21-2025
Dividend Yield
0.45%
1.75%
EPS Growth
N/A
14.49
EPS
1.75
8.51
Revenue
$6,260,300,000.00
$10,850,000,000.00
Revenue This Year
N/A
$12.37
Revenue Next Year
$3.02
$3.52
P/E Ratio
$20.84
$21.44
Revenue Growth
36.34
13.74
52 Week Low
$46.34
$148.70
52 Week High
$83.32
$197.55

Technical Indicators

Market Signals
Indicator
FTV
DGX
Relative Strength Index (RSI) 66.65 44.87
Support Level $52.57 $184.18
Resistance Level $53.55 $185.12
Average True Range (ATR) 0.94 3.22
MACD 0.10 -0.78
Stochastic Oscillator 92.37 3.85

Price Performance

Historical Comparison
FTV
DGX

About FTV Fortive Corporation

Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.2 billion in revenue in 2024.

About DGX Quest Diagnostics Incorporated

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Share on Social Networks: